Corporate Finance Adviser to

Corporate Finance Adviser to
on its initial fundraising of $8m

Corporate Finance Adviser to Fastnet Oil & Gas plc

Corporate Finance Adviser to  Fastnet Oil & Gas plc
on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Adviser to

Corporate Finance Adviser to
on its £10m Equity Placing in November 2013

Corporate Finance Adviser to

Corporate Finance Adviser to
on its £10m IPO on the AIM market of the London Stock Exchange

Trade Sale Advisor to Major Shareholder of

Trade Sale Advisor to Major Shareholder of
on its sale to RSA for €65m

Trade Sale Adviser to

Trade Sale Adviser to
  on its sale to Affinion International for €20m+

Trade Sale Adviser to

Trade Sale Adviser to
on its sale to Exponent Private Equity for €170m

Trade Sale Adviser to

Trade Sale Adviser to
on its sale to NASDAQ quoted Verint Systems for $20m+

Trade Sale Adviser to EMAP Plc

Trade Sale Adviser to EMAP Plc
on the Sale of its Irish Radio Assets for €200m
  • banner0.png
  • banner1.png
  • banner2.png
  • banner3.png

Raglan Capital was established ten years ago as a corporate finance boutique and very quickly established its reputation as a leading and successful business.

In the last couple of years, Raglan has ceased providing any third party corporate finance services as it is now solely focused upon creating its own new companies that can be rapidly listed on the London stock exchange with the general target being to complete an IPO within two to three years’ post inception.

In the past 24 months, Raglan established Amryt Pharma Plc which is now listed on both the London and Dublin stock exchanges with a market cap in excess of £50m and is now an established European orphan drug company. Amryt already has rapidly growing monthly sales revenues while at the same time managing a pipeline of drugs in development including its potential blockbuster EB orphan drug now in its final FDA phase three trials. Following on from the success Amryt Pharma, Raglan established a second orphan drug company in mid-2017, namely Open Orphan. However, this time Open Orphan aims to quickly build up a portfolio of in-licensed Orphan Drugs (drugs for rare conditions) in the EU while avoiding the risk of large, expensive clinical trials. Open Orphan is due to IPO on both the London and Dublin Stock Exchange in November 2018.

Prior to Open Orphan and Amryt, Raglan was very active in the Oil & Gas sector having established Fastnet Oil & Gas plc which floated on the London and Dublin stock exchanges raising over $50m; and another in-house Raglan creation, T5 Oil & Gas, which is due to complete its IPO before summertime 2018.

The team behind Raglan Capital have over 20 years of deal making experience with a proven track record of achieving exceptional results.

With offices in Dublin, London and Vienna, our relationships include regular contact with investment banks, private equity firms and a broad range of investors which provides Raglan Capital with invaluable access to local advisers and contacts when completing international transactions.